Evidence map›Paper›PMID 29267377›Full record

ArticlePloS one2017

Impact of genistein on the gut microbiome of humanized mice and its role in breast tumor inhibition.

Bidisha Paul, Kendra J Royston, Yuanyuan Li, Matthew L Stoll, Christine F Skibola, Landon S Wilson, Stephen Barnes, Casey D Morrow, Trygve O Tollefsbol

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 73 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Specific microbiome patterns and their association with breast cancer: the intestinal microbiota as a potential biomarker and therapeutic strategy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Bidisha PaulDepartment of Biology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Kendra J RoystonDepartment of Biology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Yuanyuan LiDepartment of Biology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Matthew L StollDivision of Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Christine F SkibolaDepartment of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Landon S WilsonTargeted Metabolomics and Proteomics Laboratory, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Stephen BarnesComprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Casey D MorrowDepartment of Cell, Development & Integrative Biology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Trygve O TollefsbolDepartment of Biology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.ORCID 0000-0002-0284-1511
University of Alabama at Birmingham · USTarget (United States) · USEmory University · US

Funding

XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Robert S Welner · 1985 to 2026
$165.9M
Why is the prevalence of obesity so high in U.S. Southern States? Regional predictors of BMI and obesity treatment response.P30DK056336 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BARBARA A GOWER · 2000 to 2026
$31.9M
UAB Center for Clinical and Translational Science (CCTS)UL1TR001417 · NCATS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KIMBERLY, ROBERT P. · 2015 to 2018
$31.4M
UAB-UCSD O'Brien Core Center for Acute Kidney Injury ResearchP30DK079337 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI AGARWAL, ANUPAM · 2008 to 2022
$18.3M
UAB Skin Diseases Research CenterP30AR050948 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI TIMARES, LAURA · 2004 to 2013
$5.5M
Combinatorial epigenetic-based prevention of breast cancerR01CA178441 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI TOLLEFSBOL, TRYGVE O · 2014 to 2025
$3.2M
Antivascular ultrasound therapy of primary liver neoplasiaR01CA204446 · NCI · UNIVERSITY OF PENNSYLVANIA · PI SEHGAL, CHANDRA M · 2017 to 2021
$2.0M
Early life prevention of breast cancer with combined epigenetic botanicalsR01CA204346 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI TOLLEFSBOL, TRYGVE O · 2017 to 2021
$1.7M
Epigenetic mechanisms of maternal diets in human health and disease preventionK01AT009373 · NCCIH · UNIVERSITY OF MISSOURI-COLUMBIA · PI LI, YUANYUAN · 2017 to 2021
$569k
5500 Q-Trap Mass SpectrometerS10RR027822 · NCRR · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BARNES, STEPHEN · 2010 to 2010
$469k
Maternal epigenetic dietary effects on early breast cancer preventionR03CA176766 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LI, YUANYUAN · 2013 to 2014
$145k
NCATS NIH HHS UL1 TR001417NCCIH NIH HHS K01 AT009373NCI NIH HHS P30 CA013148NCI NIH HHS R01 CA178441NCI NIH HHS R01 CA204346NCI NIH HHS R01 CA204446NCI NIH HHS R03 CA176766NCRR NIH HHS S10 RR027822NIAMS NIH HHS P30 AR050948NIDDK NIH HHS P30 DK056336NIDDK NIH HHS P30 DK079337NIH HHS R01 CA178441NIH HHS R01 CA2044346
6 · The paper itself

Abstract

Since dietary polyphenols can have beneficial effects in prevention and treatment of cancer, we tested the hypothesis that breast cancer patients' intestinal microbiota is modulated by genistein (GE), an isoflavone found in soy, and that microbial alterations may offset the side effects brought about by chemotherapy. We demonstrated successful humanization of germ-free mice by transplanting fecal samples from breast cancer patients before and after chemotherapy. Mice were then grouped based on chemotherapy status and GE or control diet. We did not find any significant differences between pre-chemotherapy and post-chemotherapy bacterial composition and abundances. Germ-free mice on a GE diet showed differences in microbial composition as compared to mice on control diet. Four weeks after introduction of the customized GE diet, there was distinct clustering of GE-fed mice as compared to the control-fed group. In the gut microbiome of GE-treated humanized mice, there was an increase in abundance of genera Lactococcus and Eubacterium. Phylum Verrucomicrobia showed statistically significant (p = 0.02) differences in abundances between the GE-fed and control-fed groups. There was an increase in bacteria belonging to family Lachnospiraceae and Ruminococcaceae in GE-fed mice. Marked changes were observed in GE catabolism in mice humanized with fecal material from two of three patients' post-chemotherapy with complete disappearance of 4-ethylphenol and 2-(4-hydroxyphenol) propionic acid conjugates. The post-tumor samples did not show any distinct clustering of the gut microbiota between the two diet groups. There was an increase in latency of about 25% for tumor growth of the humanized mice that were on a GE diet as compared to humanized mice on a control diet. The average tumor size for the GE group was significantly decreased compared to the non-GE group. Collectively, our results suggest that the intestinal microbiota becomes altered with a GE diet before induction of tumor. Our findings indicate that GE modulates the microbiome in humanized mice that may contribute to its effects on increasing the latency of breast tumor and reducing tumor growth.

Indexed as

Disease Models, AnimalAdultAgedAnimalsAnticarcinogenic AgentsAntineoplastic AgentsBreast NeoplasmsFecesFemaleGastrointestinal MicrobiomeGenisteinHumansMiceMiddle AgedAnticarcinogenic AgentsAntineoplastic AgentsGenistein

Identifiers

PMID29267377
PMCPMC5739415
OpenAlexW2779575947

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.